| Project/Area Number |
13557068
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
SHIMOKAWA Hiroaki Kyushu University, Dept.of Cardiovasc Med., Assoc Professor, 大学院・医学研究院, 助教授 (00235681)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUDA Takehisa Kyushu University, Dept.of Materials and Engineering, Professor, 大学院・医学研究院, 教授 (60142189)
前田 瑞夫 九州大学, 大学院・工学研究院, 教授 (10165657)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥13,800,000 (Direct Cost: ¥13,800,000)
Fiscal Year 2003: ¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 2002: ¥5,100,000 (Direct Cost: ¥5,100,000)
Fiscal Year 2001: ¥5,400,000 (Direct Cost: ¥5,400,000)
|
|---|
| Keywords | Nanotechnology / Nanocapsule / Nanomedicine / Functioning contrast medium / Nanodiagnosis / バルーン傷害 / 再狭窄 / サイトカイン / ナノカプセル(粒子) / 冠動脈インターベンション / 虚血性心臓病 |
|---|
| Research Abstract |
(1)We have demonstrated that intravenous administration of NK911, a nanoparticle containing antiproliferative drug, NK911, selectivelyaccumulates in the balloon-injured vascular lesion without endothelium and releases doxorubicin, an anti-proliferative agent, at a higher concentration.
(2)We have then demonstrated that intravenous administration of NK911 immediately after and 3 and 6 days after balloon injury markedly suppresses the development of vascular lesions at 4 weeks after the procedure in the rat carotid artery. Importantly, no adverse effects, such as weight loss, hematological disorder, and liver dysfunction, were noted. These results suggest that nano-therapy with NK911 is a promising strategy for the prevention of restenosis after percutaneous coronary intervention(PCI).
(3)We have developed a new stent that is coated with endothelial progenitor cells on it. We have confirmed that with this new stent, vascular re-endothelialization is enhanced as compared with a conventional stent.
(4)We have developed a new MRI contrast medium that detects the de-endothelialized vascular lesion. This concept is based on the observation that Evans-blue selectively accumulates into the de-endothelialized lesion. With this new contrast medium we have demonstrated that we are able to detect the de-endothelialized lesion in the rat carotid artery in vivo.
|
